Evaluation criteria

N = 11

Study design

1) Description of the setting (dates, period of enrolment)

9 (82%)

2) Inclusion and exclusion criteria were described

11 (100%)

3) Justification explained for the selected study population size

7 (64%)

4) Details of the interventions (pharmacological or non-pharmacological treatment), to allow replication

11 (100%)

5) Details on efficacy assessment were described

11 (100%)

6) Statistical methods were clearly described

10 (91%)

7) Randomised trial

7 (64%)

8) Multicentric study

4 (36%)

Neuropathy-related

9) Neuropathy assessment criteria described (NCI-CTCAE criteria or neuropathy questionnaire)

10 (91%)

10) A neuropathy exam was performed

2 (18%)

11) Neurophysiological testing was performed

0 (0%)

12) Chronic CIPN was defined or implied

4 (36%)

Study population

13) The clinical variables “age”, “sex” and “cancer disease” was described

9 (82%)

14) Inclusion of patients undergoing exclusively to oxaliplatin-based ChT

3 (27%)

15) Oxaliplatin regimen and cumulative dose were described

1 (9%)

Results

16) Number of patients reported at each group or subgroup (eligible, included, analysed)

10 (91%)

17) Number of patients undergoing oxaliplatin-based ChT

7 (64%)

18) Description objectively response in CIPN relief

9 (82%)

19) Addressed limitations and potential sources of bias

7 (64%)